Genprex, which is developing gene-based nanoparticle therapies to treat cancer, raised $6.4 million by offering 1.28 million shares at $5 per share. At that price, it commands a fully diluted IPO market cap of $75 million.
Genprex plans to list on the Nasdaq under the symbol GNPX. Network 1 Financial Securities acted as a lead manager on the deal.
